FDA On June 13 Updates Advice To Manufacturers Of Covid-19 Vaccines (2024-2025 Formula), Says If Feasible Use KP.2 Strain Of JN.1-Lineage
Portfolio Pulse from Benzinga Newsdesk
The FDA has updated its advice to manufacturers of COVID-19 vaccines for the 2024-2025 formula, recommending the use of the KP.2 strain of the JN.1-lineage if feasible.
June 14, 2024 | 6:13 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
The FDA's updated advice on COVID-19 vaccines may have a broader impact on the market, potentially affecting the SPY ETF.
While the FDA's advice is specific to vaccine manufacturers, the broader market, including SPY, may see some impact due to the significance of these companies.
CONFIDENCE 70
IMPORTANCE 50
RELEVANCE 50
POSITIVE IMPACT
AstraZeneca may need to adjust its COVID-19 vaccine formula to include the KP.2 strain of the JN.1-lineage as recommended by the FDA.
AstraZeneca is a major COVID-19 vaccine manufacturer and will likely follow FDA recommendations, potentially boosting investor confidence.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
BioNTech, in partnership with Pfizer, may need to update its COVID-19 vaccine to include the KP.2 strain of the JN.1-lineage as per FDA advice.
BioNTech, a key player in COVID-19 vaccines, will likely adhere to FDA guidelines, which could positively impact its stock.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Johnson & Johnson may need to incorporate the KP.2 strain of the JN.1-lineage into its COVID-19 vaccine for the 2024-2025 season as per FDA guidance.
Johnson & Johnson, a significant COVID-19 vaccine producer, will likely follow FDA recommendations, potentially boosting investor sentiment.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Moderna is advised by the FDA to use the KP.2 strain of the JN.1-lineage in its COVID-19 vaccine for the 2024-2025 season.
Moderna, a leading COVID-19 vaccine manufacturer, will likely adhere to FDA guidelines, which could positively impact its stock.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Novavax may need to update its COVID-19 vaccine to include the KP.2 strain of the JN.1-lineage as per FDA advice.
Novavax, a key player in COVID-19 vaccines, will likely adhere to FDA guidelines, which could positively impact its stock.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Pfizer, in partnership with BioNTech, may need to update its COVID-19 vaccine to include the KP.2 strain of the JN.1-lineage as per FDA advice.
Pfizer, a major COVID-19 vaccine manufacturer, will likely follow FDA recommendations, potentially boosting investor confidence.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80